Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...

NovoCure’s Optune Lua, a wearable indicated for patients with metastatic non-small cell lung cancer has received approval ...

On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment. Read why I upgrade NVCR stock from buy ...

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.

U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average ...

Fintel reports that on October 16, 2024, HC Wainwright & Co. upgraded their outlook for NovoCure (NasdaqGS:NVCR) from Neutral ...

Optune Lua is designed for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have experienced disease progression after platinum-based chemotherapy. Asaf Danziger, CEO of Novocure ...

Inflation's downward trajectory, combined with slowing wage growth, emphasizes BOE Governor Bailey's recent comments that more aggressive interest rate cuts are possible, Swissquote Bank said, adding ...

Highlights:,Significant Stock Surge:,NovoCure's shares rose by 10.7% to $17.78, driven by substantial trading volume following FDA approval of its Optune Lua device for metastatic non-small cell lung ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...